2型糖尿病患者20年心血管并发症与危险因素趋势:瑞典全国队列研究
该研究基于瑞典国家糖尿病登记库679 072例2型糖尿病患者及2 643 800名匹配对照,分析2001-2019年心血管事件与代谢危险因素趋势。结果显示动脉粥样硬化并发症发生率下降,但心力衰竭发生率在2013年左右进入平台期;糖化血红蛋白、收缩压、估算肾小球滤过率和血脂与结局独立相关,体重指数单独可解释超过30%的心衰风险。
要点
- 2型糖尿病患者动脉粥样硬化并发症发生率下降,但心衰发生率2013年后趋于平台。
- 糖化血红蛋白和收缩压对动脉粥样硬化事件预后最重要,体重指数对心衰最重要。
- 即使所有危险因素达标,2型糖尿病仍与心衰风险增加独立相关(HR 1.50)。
核心结论
- 2型糖尿病患者动脉粥样硬化并发症和心衰发生率总体下降,但心衰发生率近年趋于平台。
- 可改变危险因素达标与结局风险降低相关,收缩压和糖化血红蛋白对动脉粥样硬化结局尤其重要,体重指数对心衰尤其重要。
- 即使无危险因素超过目标值,2型糖尿病仍与心衰风险增加独立相关(HR 1.50,95%CI 1.35-1.67)。
研究设计与样本
- 基于瑞典国家糖尿病登记库的全国性队列研究,纳入679 072例2型糖尿病患者和2 643 800名匹配对照。
- 分析2001-2019年冠心病、急性心肌梗死、脑血管病和心衰的发病趋势。
- 采用Cox回归和标准化发病率分析首次事件时间趋势及危险因素与结局的关联。
主要发现
- 2型糖尿病患者每10 000人年发病率2001年与2019年分别为:急性心肌梗死73.9(95%CI 65.4-86.8)与41.0(95%CI 39.5-42.6);冠心病205.1(95%CI 186.8-227.5)与80.2(95%CI 78.2-82.3);脑血管病83.9(95%CI 73.6-98.5)与46.2(95%CI 44.9-47.6);心衰98.3(95%CI 89.4-112.0)与75.9(95%CI 74.4-77.5)。
- 心衰发病率在2013年左右进入平台期并持续。
- 2型糖尿病患者中糖化血红蛋白、收缩压、估算肾小球滤过率和血脂与结局独立相关。
- 体重指数单独可解释超过30%的心衰风险。
- 2型糖尿病无危险因素超过目标值者,除心衰外心血管风险与对照无显著差异;冠心病和脑血管病风险随每个未达标危险因素逐步增加。
临床怎么用
- 对2型糖尿病患者应综合管理血糖、血压、血脂和肾功能以降低动脉粥样硬化事件风险。
- 心衰预防需特别关注体重管理,体重指数对心衰风险贡献显著。
- 即使危险因素达标,仍需警惕2型糖尿病患者的心衰风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The goal of this work was to investigate trends (2001-2019) for cardiovascular events and cardiometabolic risk factor levels in individuals with type 2 diabetes (T2D) and matched control subjects. METHODS: This study included 679 072 individuals with T2D from the Swedish National Diabetes Register and 2 643 800 matched control subjects. Incident outcomes comprised coronary artery disease, acute myocardial infarction, cerebrovascular disease, and heart failure (HF). Trends in time to first event for each outcome were analyzed with Cox regression and standardized incidence rates. In the group with T2D, Cox regression was also used to assess risk factor levels beyond target and outcomes, as well as the relative importance of each risk factor to each model. RESULTS: Among individuals with T2D, incidence rates per 10 000 person-years in 2001 and 2019 were as follows: acute myocardial infarction, 73.9 (95% CI, 65.4-86.8) and 41.0 (95% CI, 39.5-42.6); coronary artery disease, 205.1 (95% CI, 186.8-227.5) and 80.2 (95% CI, 78.2-82.3); cerebrovascular disease, 83.9 (95% CI, 73.6-98.5) and 46.2 (95% CI, 44.9-47.6); and HF, 98.3 (95% CI, 89.4-112.0) and 75.9 (95% CI, 74.4-77.5). The incidence for HF plateaued around 2013, a trend that then persisted. In individuals with T2D, glycated hemoglobin, systolic blood pressure, estimated glomerular filtration rate, and lipids were independently associated with outcomes. Body mass index alone potentially explained >30% of HF risk in T2D. For those with T2D with no risk factor beyond target, there was no excess cardiovascular risk compared with control subjects except for HF, with increased hazard with T2D even when no risk factor was above target (hazard ratio, 1.50 [95% CI, 1.35-1.67]). Risk for coronary artery disease and cerebrovascular disease increased in a stepwise fashion for each risk factor not within target. Glycated hemoglobin was most prognostically important for incident atherosclerotic events, as was body mass index for incident of HF. CONCLUSIONS: Risk and rates for atherosclerotic complications and HF are generally decreasing among individuals with T2D, although HF incidence has notably plateaued in recent years. Modifiable risk factors within target levels were associated with lower risks for outcomes. This was particularly notable for systolic blood pressure and glycated hemoglobin for atherosclerotic outcomes and body mass index for heart failure.
引用
- Sattar N, McMurray J, Borén J, et al. Twenty Years of Cardiovascular Complications and Risk Factors in Patients With Type 2 Diabetes: A Nationwide Swedish Cohort Study. Circulation. 2023. PMID: 37154040. doi:10.1161/CIRCULATIONAHA.122.063374
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。